September 16, 2021
September 16, 2021 – The U.S. FDA has approved two new indications for Brukinsa® (zanubrutinib), the first to treat adults who have Waldenström's macroglobulinemia
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
GlobalReach Health
September 16, 2021
September 16, 2021 – The U.S. FDA has expanded the emergency use authorization (EUA) for Eli Lilly's investigation drugs bamlanivimab and etesevimab
September 13, 2021
September 13, 2021 – Jacobus Pharmaceutical Company recalled three lots of Ruzurgi® (amifampridine) 10mg tablets. Laboratory test found
September 12, 2021
September 17, 2022 – Cabometyx® (cabozantinib) is now U.S. FDA approved for to treat patients at least
12 years old who are radioactive iodine-refractory
September 8, 2021
September 8, 2021 – Azurity Pharmaceuticals has recalled one lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50mg/mL Kit
September 7, 2021
September 7, 2021 – ICU Medical has issued a recall for one lot of Aminosyn II 15%, Amino Acid Injection, Sulfite Free intravenous (IV) solution to the hospital
September 1, 2021
September 1, 2021 – Invega HafyeraTM (paliperidone palmitate) extended-release injectable suspension is
now the first FDA-approved twice-yearly treatment for schizophrenia
September 1, 2021
September 1, 2021 – The U.S. FDA is requiring new and updated warnings on a class of drugs called JAK inhibitors due to an increased risk of cancer